An injection pen of Zepbound, Eli Lilly's weight loss drug, is displayed in New York City on December 11, 2023.
Brendan McDermid | Reuters
All cans of Eli Lilly's The hugely popular weight-loss injection Zepbound and the diabetes drug Mounjaro are now available in the U.S., according to an update to the U.S. Food and Drug Administration's drug shortage database on Friday.
An earlier update said some doses of the treatments were still in short supply. Some doses of Mounjaro have been in short supply since 2022, while doses of Zepbound entered the FDA's shortage list earlier this year following its U.S. approval in November.
Demand for weight loss and diabetes drugs has exceeded supply for months, forcing Eli Lilly and its competitor Novo Nordisk billions to boost production.
The FDA update comes a day after Eli Lilly CEO David Ricks told Bloomberg that shortages of Mounjaro and Zepbound would end “very soon.”
“I think we plan to finish this process today or tomorrow,” he told the outlet in an interview.
A spokesperson for Eli Lilly did not immediately respond to CNBC's request for comment on the FDA's update on Friday.
According to the FDA database, all doses of Novo Nordisk's diabetes injection drug Ozempic have been available in the U.S. since Friday. Meanwhile, the FDA said some doses of Novo Nordisk's weight-loss drug Wegovy are only available in limited quantities.
Comments are closed.